EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population

Yogesh Patel iD, Larry Orogun, Nicole Yocum, Louise R Rodino-Klapac, Lilly East

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Yogesh Patel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Models, Biological, Morpholinos, Oligonucleotides, Antisense. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is characterized by progressive, irreversible muscle damage that usually leads to premature death from cardiac or respiratory failure. Eteplirsen is a phosphorodiamidate morpholino oligomer and the first antisense oligonucleotide (ASO) approved for the treatment of patients with exon 51 skip‐amenable DMD. This analysis presents the first population pharmacokinetics (PK) modeling and simulation performed for the ASO drug class in DMD. Study objectives were to characterize the population PK of eteplirsen in patients with DMD across a broad age range and to identify the impact of covariates on eteplirsen exposure to guide clinical dosing. Plasma concentration data were pooled from six clinical studies of male patients with DMD across the age range of 6 months to 4 years (1 study) and 4–16 years (5 studies). Doses ranged from 0.5 to 50 mg/kg/week across different studies. A three‐compartment model with a linear elimination described the eteplirsen plasma concentration data well. Body weight effect on all PK parameters and eGFR, and age (≤ 4 years vs. > 4 years) effect on systemic clearance were key determinants of variability in the final model. Simulations showed similar exposures for eteplirsen (30 mg/kg intravenously once weekly) across different age groups (0.5 to < 2, 2 to < 4, 4 to < 7, and 7 to ≤ 16 years). These findings support the existing eteplirsen dosing paradigm of uniform weight‐based dosing at 30 mg/kg/week across the broad age range of the target DMD population (6 months to adolescence).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneModels, BiologicalMorpholinosOligonucleotides, AntisenseHumansMaleChild, PreschoolAdolescentChildInfantDose-Response Relationship, DrugComputer SimulationBody Weight

Stichwörter der Autor:innen

dosepediatricpharmacokineticspopulation

Substanzen

eteplirsenMorpholinosOligonucleotides, Antisense

Autor:innen und Institutionen

  • Sarepta Therapeutics, Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Yogesh Patel

Zitieren

APA

Patel, Y., Orogun, L., Yocum, N., Rodino-Klapac, L. R., & East, L. (2025). A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70001

Vancouver

Patel Y, Orogun L, Yocum N, Rodino-Klapac LR, East L. A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70001

BibTeX
@article{Patel2025,
  author = {Patel, Yogesh and Orogun, Larry and Yocum, Nicole and Rodino-Klapac, Louise R and East, Lilly},
  title = {A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70001}
}
Kostenlos starten →